Please login to the form below

Not currently logged in
Email:
Password:

alpelisib

This page shows the latest alpelisib news and features for those working in and with pharma, biotech and healthcare.

Cosentyx, Entresto drive topline growth for Novartis in Q4

Cosentyx, Entresto drive topline growth for Novartis in Q4

Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics